Celgene
Celgene appoints European haematology and oncology head
May 7, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, Michael Zaiac
Swiss-based Celgene International SÃ rl has appointed Michael Zaiac to the position of vice president of medical affairs for its European haematology …
AstraZeneca looks to oncology match-ups to boost sales
April 24, 2015Sales and Marketing AstraZeneca, Brilinta, Celgene, Innate, Juno, farxiga, ticagrelor
AstraZeneca posted a 1% increase in revenue in its first-quarter 2015 financials – and is investing the money to back …
Celgene appoints former Cubist chief executive
April 20, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, cubist, michael bonney
Celgene has elected pharma veteran Michael Bonney to join its board of directors. Bonney served as chief executive and board …
NICE decisions made on Bayer, Celgene and Boehringer drugs
March 26, 2015Sales and Marketing Bayer, Boehringer, Celgene, NHS, Xarelto, imnovid, jardiance
In final guidance NICE has recommended Bayer’s Xarelto and Boehringer’s Jardiance for NHS funding, but not Celgene’s Imnovid. Bayer’s Xarelto …
Pfizer, Novartis and Celgene among late-stage psoriasis trial advances
March 23, 2015Sales and Marketing Celgene, Cosentyx, Enbrel, FDA, Novartis, Pfizer, otezla, psoriasis, tofacitinib
Pfizer bosses say they are confident of a positive FDA application for tofacitinib after announcing positive Phase III study results. …
Precision medicine: the future of cancer treatment?
March 2, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, Cancer, Celgene, Precision, melanoma, oncology, underwood
There are plenty of advances in oncology treatments to be excited about – from immunotherapy to cancer vaccines and monoclonal …
Celgene gets FDA licence extension for myeloma drug
February 19, 2015Sales and Marketing Celgene, FDA, Revlimid, lenalidomide, myeloma
The FDA has given Celgene an extended licence for its multiple myeloma drug Revlimid (lenalidomid), to include people who are …
Celgene’s blood cancer pill too expensive for NHS
February 13, 2015Sales and Marketing Celgene, NHS, NICE, Pomalidomide, imnovid, myeloma
NICE has decided not to recommend Celgene’s Imnovid for treating patients with multiple myeloma – a cancer that affects white …
Celgene UK: market access is a complex business
December 15, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abraxane, CDF, Cancer, Celgene, PPRS, Revlimid, market access, sam pierce
Being a firm that specialises in cancer drugs, Celgene UK is no stranger to England’s notoriously rigorous approach to expensive …
Celgene appoints new UK general manager
December 9, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, Wim Souverijns
Celgene has appointed Wim Souverijns as its new vice president and general manager for UK and Ireland. Souverijns (pictured) takes …
Celgene expands immunotherapy pipeline with Sutro
October 27, 2014Research and Development, Sales and Marketing Celgene, PD-1 and PD-L1, Q3, oncology, sutro
Celgene has extended its collaboration with Sutro Biopharma and added a buyout option for the firm as the two companies …
Celgene rebuffed by NICE over cancer drug
September 9, 2014Sales and Marketing Abraxane, Cancer, Celgene, Gemzar, NICE, gemcitabine, nab-paclitaxel
In new draft guidance NICE says that Celgene’s Abraxane (nab-paclitaxel) taken with Lilly’s Gemzar (gemcitabine) should not be funded by …
NICE won’t back Revlimid in new setting
July 31, 2014Medical Communications, Sales and Marketing Celgene, NICE, Revlimid, Thalidomide, multiple myeloma
NICE has once again said it does not think that Celgene’s rare cancer drug Revlimid should be used on the …
Working Life: Celgene’s Rob Moore
July 14, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, Working Life, rob moore
How did you find your way into your current role? I joined the pharmaceutical industry almost 20 years ago with …
Scottish Medicines Consortium disappoints Celgene
July 8, 2014Sales and Marketing Celgene, SMC, Scottish Medicines Consortium, imnovid, myeloma
Celgene admitted it is ‘disappointed’ with the Scottish Medicines Consortium decision not to recommend blood cancer therapy Imnovid for patients …
Latest content
FibroFind appoints Lee Borthwick as CEO
